Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immunome Inc. Director's Dealing 2020

Oct 9, 2020

32238_dirs_2020-10-08_a183ffb2-6f24-46ec-a7d3-d38beedaaac7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2020-10-06

Reporting Person: Widlitz Michael (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-10-06 Common Stock C 51315 Acquired 51315 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-10-06 Series A Convertible Preferred Stock $ C 51315 Disposed Common Stock (51315) Direct

Footnotes

F1: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the
Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.